Bristol widens drug-licensing partnership with Ono

09/21/2011 | Reuters

Bristol-Myers Squibb gained rights to investigational cancer immunotherapy BMS-936558/ONO-4538 in all countries except Taiwan, Japan and South Korea through an expanded agreement with Ono Pharmaceutical. Bristol already had exclusivity in North America. In exchange, Ono gets co-development and -marketing rights in Japan to Orencia, Bristol's rheumatoid arthritis drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID